Search 

Aptus Clinical is a clinical research provider formed by three former AstraZeneca colleagues who have over 75 years’ combined drug development experience.



Our mission is to be the partner of choice for biopharmaceutical companies and academic researchers, supporting them in their quest to develop new and valued medicines. We understand the challenges faced by our clients and will provide key insight and experience to meet the needs of our customers by delivering operational excellence in order to achieve the exacting standards of the industry

 

With experience ranging from early methodology studies and first time in man, through proof of concept to Phase III registration and clinical pharmacology studies this  breadth and depth of knowledge is at the disposal of our customers.



We recognise that the increasing legislative, regulatory, ethical and patient focused expectations being placed on the conduct of clinical studies, is making their successful conduct and delivery ever more costly and difficult to achieve.



With this in mind, Aptus Clinical is continually developing a team of highly experienced clinical research experts who have extensive insight into the effective delivery of studies and are passionate about partnering with biotechs, pharma and academia to provide bespoke clinical delivery solutions.



Whether you are a company or academic institution looking for strategic input to study designs or need access to flexible, cost effective and experienced clinical research resources to deliver high quality studies, then please get in touch.

Precision is the first global precision medicine clinical research services organization, purpose-built to improve the clinical research and development process for new therapeutics. Our novel approach integrates clinical operations excellence, with laboratory expertise, and advanced data sciences to inform every step. This maximizes our clients’ insight into patient biology, delivering more predictable trial outcomes and accelerating clinical development. We apply our expertise to trials at all stages—from early development through approval—with embedded experience in oncology and rare disease. With over 2000 dedicated professionals and 35 offices worldwide, we stand ready to help accelerate life-changing treatments anywhere around the globe.

Sygnature Discovery - enabling success in drug discovery

Sygnature Discovery (www.sygnaturediscovery.com ) is a leading independent provider of integrated drug discovery resource and expertise.  Since 2011, 33 compounds discovered by Sygnature for clients have entered pre-clinical development and so far 17 of these have progressed to clinical trials (Phases I, II and III).

We add considerable value to our clients'​ research projects by providing intellectual input and drug discovery expertise to accelerate target validation, hit identification, hit-to-lead, lead optimisation and drug discovery programmes.  Sygnature's capabilities include medicinal chemistry, in vitro biology, computational chemistry and informatics, DMPK, and protein crystallography (via affiliate company Peak Proteins).  We can also provide pre-clinical experimental services support through our sister company RenaSci.

Sygnature Discovery operates a business whose primary focus is value creation for our clients, through the application of integrated drug discovery know-how and close working relationships.  We have built a team of over 400 staff including pharmaceutical industry-experienced research scientists (over 80% PhD qualified) with the ability to collaborate on an equal footing with our clients’ scientists to drive drug discovery projects towards the clinic.

In summary, Sygnature Discovery offers:

•    Target validation
•    Hit identification
•    Hit-to-lead
•    Lead optimisation
•    Integrated drug discovery programmes
•    Medicinal chemistry
•    In vitro biology (including biophysics and live cell imaging)
•    Computational chemistry
•    DMPK
•    Protein crystallography

SYNthesis is a chemistry-focussed, contract research organisation providing custom synthesis and medicinal chemistry services.
The company was established in 2007 and operates a unique, hybrid business model combining medicinal chemistry & project management expertise based in both Australia and the USA, with high quality synthetic chemistry based in China.
In addition to Melbourne (Australia) where SYNthesis med chem's global headquarters are located, the company also has operations in Shanghai & Suzhou (China) together with offices in the UK and USA.
SYNthesis currently employs over 250 chemists based in Australia, China & the USA.
Our medicinal chemists provide the design, innovation, creativity and problem solving expertise required to complement the skills & capabilities of the company's expert team of synthetic chemists based in China.
Our medicinal chemists are all experienced and highly skilled scientists with a track record of delivering clinical candidates, a passion for discovering new medicines and a comprehensive insight gained from managing more than 100 projects covering all phases of the pharmaceutical R&D process.
They also act as project managers for custom synthesis and medicinal chemistry projects.